Performance
Day's Low
Day's High
₹830₹858.9552 Week's Low
52 Week's High
₹725₹1,175.9
| Returns % | |
| 1 Month Return | -24.52 % |
| 3 Month Return | + 6.16 % |
| 1 Year Return | + 6.16 % |
| Market Stats | |
| Previous Close | ₹845.30 |
| Open | ₹858.95 |
| Volume | 1.08L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹13,304.51Cr |
Key Statistics
| P/E Ratio | 0 |
| PEG Ratio | 0 |
| Market Cap | ₹1,690.10 Cr |
| P/B Ratio | 6.26 |
| EPS | 31.95 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 21.67 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| NA | ₹1,690.10 Cr | 487.73% | 0.54 | ₹30 Cr | ₹227 Cr | |
| BUY | ₹12,743.87 Cr | 377.48% | 0.51 | ₹314 Cr | ₹2,177 Cr | |
| NA | ₹190.28 Cr | 106.75% | 0.73 | NA | NA | |
| BUY | ₹12,558.73 Cr | 55.97% | 0.66 | -₹95 Cr | ₹4,051 Cr | |
| NA | ₹376.46 Cr | 9.34% | 0.00 | NA | NA |
Mutual Fund Holdings
Company Information
Share Price: ₹841.15 per share as on 19 Sep, 2024 04:01 PM
Market Capitalisation: ₹13,304.51Cr as of today
Revenue: ₹1,019.11Cr as on June 2024 (Q2 24)
Net Profit: ₹61.21Cr as on June 2024 (Q2 24)
Listing date: 06 Aug, 2024
| Organisation | Akums Drugs & Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Akums Drugs & Pharmaceuticals Ltd
Akums Secures Patent for Sickle Cell Treatment - 13 Sep, 2024
Akums Drugs and Pharmaceuticals has been awarded a patent for a room temperature stable oral suspension of Hydroxyurea, aimed at managing Sickle Cell Disease. This formulation promises to be a cost-effective alternative to imported solutions, reinforcing Akums' commitment to affordable healthcare.
Akums Drugs Expands into European Market - 30 Aug, 2024
Akums Drugs and Pharmaceuticals is expanding its global presence by filing dossiers in the EU and achieving GMP certification for two facilities. This strategic move aims to enhance revenue and market presence amid US market volatility.
Akums Drugs Faces Recall of Pentids Tablets - 28 Aug, 2024
Akums Drugs & Pharmaceuticals Ltd is voluntarily recalling batches of Pentids 800, 400, and 200 tablets. Pharmacies and retailers have been instructed to halt sales of these products.
Akums Drugs Returns to Profit in Q1 Earnings - 27 Aug, 2024
Akums Drugs and Pharmaceuticals reported a standalone net profit of ₹42 crore for Q1 FY2024, a significant recovery from a net loss of ₹19 crore last year. Consolidated net profit reached ₹61 crore, driven by strong growth in the CDMO segment. Revenue also improved year-on-year, indicating a positive turnaround for the company.
Akums Drugs Reports Strong Q1 Turnaround - 26 Aug, 2024
Akums Drugs and Pharmaceuticals reported a net profit of Rs 60 crore for Q1 FY25, a significant recovery from last year's loss. Total income rose to Rs 1,026 crore, driven by growth in its CDMO segment. The company also announced plans to establish two new production facilities in Jammu, investing Rs 265 crore to enhance manufacturing capabilities.
Insights on Akums Drugs & Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 0.00% to 9.09% in Aug 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 0.00% to 5.32% in Aug 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 0.00% to 3.07% in Aug 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 7 days, AKUMS stock has moved down by -7.2%
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 84.91% to 75.26% in Aug 2024 quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 75.26% | ||
| Foreign Institutions | 5.32% | 0.00 | |
| Mutual Funds | 3.07% | 0.00 | |
| Retail Investors | 9.09% | 0.00 | |
| Others | 7.26% |
Key Indicators
Earnings and Dividends
Akums Drugs & Pharmaceuticals Ltd Earnings Results
Akums Drugs & Pharmaceuticals Ltd’s net profit jumped 131.97% since last year same period to ₹60.17Cr in the Q1 2024-2025. On a quarterly growth basis, Akums Drugs & Pharmaceuticals Ltd has generated 245.62% jump in its net profits since last 3-months.
Read More about Earnings Results
Technicals Summary
Bearish
Neutral
Bullish
Akums Drugs & Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Akums Drugs & Pharmaceuticals Ltd shares.
Akums Drugs & Pharmaceuticals Ltd (AKUMS) share price today is ₹841.15
Akums Drugs & Pharmaceuticals Ltd is listed on NSE
Akums Drugs & Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Akums Drugs & Pharmaceuticals Ltd is ₹858.95.
- Today’s lowest price of Akums Drugs & Pharmaceuticals Ltd is ₹830.
Today’s traded volume of Akums Drugs & Pharmaceuticals Ltd(AKUMS) is 1.08L.
Today’s market capitalisation of Akums Drugs & Pharmaceuticals Ltd(AKUMS) is ₹13304.51Cr.
| Akums Drugs & Pharmaceuticals Ltd(AKUMS | Price |
|---|---|
52 Week High | ₹1175.9 |
52 Week Low | ₹725 |
Akums Drugs & Pharmaceuticals Ltd(AKUMS) share price is ₹841.15. It is down -28.47% from its 52 Week High price of ₹1175.9
Akums Drugs & Pharmaceuticals Ltd(AKUMS) share price is ₹841.15. It is up 16.02% from its 52 Week Low price of ₹725
| Akums Drugs & Pharmaceuticals Ltd(AKUMS | Returns |
|---|---|
1 Day Returns | -4.15% |
1 Month Returns | -24.52% |
3 Month Returns | 6.16% |
1 Year Returns | 6.16% |